SCHEMBL420790

SCHEMBL420790

CCOC(=O)c1cc(-c2cc(F)cc(C#N)c2)c(-c2cccc(C#N)c2)o1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 1/20 0.43
TLR7 Q9NYK1 1/20 0.43
FNTA P49354 1/20 0.43
FNTB P49356 1/20 0.43
CNR2 P34972 1/20 0.42
PGR P06401 1/20 0.42
HRH2 P25021 1/20 0.40
HRH1 P35367 1/20 0.40
ALDH1A1 P00352 2/20 0.39
LMNA P02545 1/20 0.39
PDCD1 Q15116 1/20 0.39
CD274 Q9NZQ7 1/20 0.39
SETD7 Q8WTS6 1/20 0.39
POLB P06746 1/20 0.38
NLRP3 Q96P20 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
TRPM8 Q7Z2W7 1/20 0.37
KDM4E B2RXH2 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL419840 0.93 FNTA (0.42) TLR8TLR7FNTAFNTBCNR2
SCHEMBL420126 0.92 ALOX5 (0.45) TLR8TLR7FNTAFNTBPGR
SCHEMBL418491 0.86 PGR (0.41) PGRALDH1A1POLBKDM4EHPGD
SCHEMBL2506526 0.84 PGR (0.42) TLR8TLR7FNTAFNTBCNR2
SCHEMBL419285 0.81 FNTA (0.46) TLR8TLR7FNTAFNTBCNR2
SCHEMBL2516005 0.78 CNR2 (0.40) TLR8TLR7FNTAFNTBCNR2
SCHEMBL420175 0.77 PTGDR2 (0.40) FNTAFNTB
SCHEMBL2507675 0.77 PGR (0.40) CNR2PGRHRH2HRH1ALDH1A1
SCHEMBL421428 0.76 PRKDC (0.42) ALDH1A1PDCD1CD274TRPM8HPGD
SCHEMBL31341168 0.74 PGR (0.42) PGRLMNANLRP3NPSR1GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376479-B1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO KG (DE) 2016-03-02 EP disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AADAC, DDC, TPMT TLR8 1239/4885TLR7 1264/4885FNTA 725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.